{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:36:43Z","timestamp":1787564203454,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabres.2025.112430","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:11:18Z","timestamp":1755738678000},"page":"112430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Association between SGLT2 inhibitor therapy and prolonged dementia-free survival in older adults with type 2 diabetes: a retrospective cohort study from Germany"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2385-5200","authenticated-orcid":false,"given":"Theresia","family":"Sarabhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9954-3245","authenticated-orcid":false,"given":"Rebecca","family":"Zingel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9576-7858","authenticated-orcid":false,"given":"Jens","family":"Bohlken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7227","authenticated-orcid":false,"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.112430_b0005","series-title":"Fact Sheets of Dementia","author":"Organization","year":"2021"},{"issue":"1","key":"10.1016\/j.diabres.2025.112430_b0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1474-4422(05)70284-2","article-title":"Risk of dementia in diabetes mellitus: a systematic review","volume":"5","author":"Biessels","year":"2006","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.diabres.2025.112430_b0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.diabres.2025.112430_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310964","article-title":"Age at diagnosis of diabetes, obesity, and the risk of dementia among adult patients with type 2 diabetes","volume":"19","author":"Qi","year":"2024","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.diabres.2025.112430_b0025","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S2213-8587(20)30267-9","article-title":"The link between type 2 diabetes and dementia: from biomarkers to treatment","volume":"8","author":"Beeri","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10248","key":"10.1016\/j.diabres.2025.112430_b0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.diabres.2025.112430_b0035","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3233\/JAD-215678","article-title":"Association between use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and cognitive function in a longitudinal study of patients with type 2 diabetes","volume":"87","author":"Low","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"23","key":"10.1016\/j.diabres.2025.112430_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.diabres.2025.112430_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106062","article-title":"Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment","volume":"176","author":"Rizzo","year":"2022","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.diabres.2025.112430_b0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jphs.2016.02.003","article-title":"Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects","volume":"130","author":"Tahara","year":"2016","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.diabres.2025.112430_b0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/biof.1998","article-title":"Dapagliflozin improves diabetic cognitive impairment via indirectly modulating the mitochondria homeostasis of hippocampus in diabetic mice","volume":"50","author":"Gui","year":"2024","journal-title":"Biofactors"},{"issue":"6","key":"10.1016\/j.diabres.2025.112430_b0060","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00125-021-05393-8","article-title":"Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study","volume":"64","author":"Biessels","year":"2021","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.diabres.2025.112430_b0065","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2337\/dc19-0783","article-title":"Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial","volume":"42","author":"Biessels","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112430_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079475","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2025.112430_b0075","article-title":"Correlation between the utilization of sodium-glucose cotransporter-2 (SGLT2) inhibitors and the risk of dementia: a nationwide population-based study in Taiwan","author":"Chuang","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.diabres.2025.112430_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.747620","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population-based study with competing risk analysis","volume":"8","author":"Mui","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.112430_b0085","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/WAD.0b013e3181a6bebc","article-title":"Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors","volume":"23","author":"Bradford","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"11","key":"10.1016\/j.diabres.2025.112430_b0090","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.amjmed.2024.06.030","article-title":"Association between SGLT2 inhibitors and risk of dementia and Parkinson's disease: a meta-analysis of 12 randomized controlled trials","volume":"137","author":"Jaiswal","year":"2024","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.diabres.2025.112430_b0095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5414\/CP203320","article-title":"Basic characteristics and representativeness of the German Disease Analyzer database","volume":"56","author":"Rathmann","year":"2018","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.diabres.2025.112430_b0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/dom.14226","article-title":"Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes","volume":"23","author":"Neuen","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.diabres.2025.112430_b0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium\u2013glucose cotransporter 2 inhibitors with time to dementia: a population-based Cohort study","volume":"46","author":"Wu","year":"2022","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.diabres.2025.112430_b0110","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209805","article-title":"SGLT2 inhibitor use and risk of Dementia and Parkinson disease among patients with type 2 diabetes","volume":"103","author":"Kim","year":"2024","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.diabres.2025.112430_b0115","first-page":"30","article-title":"Dementia in Germany: epidemiology, trends and challenges","volume":"8","author":"Georges","year":"2023","journal-title":"J Health Monit"},{"issue":"7\u20138","key":"10.1016\/j.diabres.2025.112430_b0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10354-020-00803-9","article-title":"Factors influencing general practitioners' perception of and attitude towards dementia diagnostics and care-results of asurvey among primary care physicians in Germany","volume":"171","author":"Wangler","year":"2021","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.diabres.2025.112430_b0125","article-title":"Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: a systematic review and meta-analysis","volume":"26","author":"Rivera","year":"2023","journal-title":"Am Heart J Plus"},{"issue":"2","key":"10.1016\/j.diabres.2025.112430_b0130","article-title":"Prevalence of type 2 diabetes mellitus and its associated risk factors in an urban slum of a metropolitan city","volume":"2","author":"Qureshi","year":"2025","journal-title":"Prevent Med: Res Rev"},{"issue":"5","key":"10.1016\/j.diabres.2025.112430_b0135","article-title":"Recent and upcoming therapies for management of type 2 diabetes: a review","volume":"1","author":"Gokalani","year":"2024","journal-title":"Prevent Med: Res Rev"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725004449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725004449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:24:41Z","timestamp":1764080681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725004449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"alternative-id":["S0168822725004449"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112430","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between SGLT2 inhibitor therapy and prolonged dementia-free survival in older adults with type 2 diabetes: a retrospective cohort study from Germany","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112430"}}